Abunada A, Sirhan Z, Thyagarajan A, Sahu RP. Tyrosine kinase inhibitors and
human epidermal growth factor receptor-2 positive breast cancer.
World J Clin Oncol 2023;
14:198-202. [PMID:
37275938 PMCID:
PMC10236985 DOI:
10.5306/wjco.v14.i5.198]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/09/2023] [Revised: 02/28/2023] [Accepted: 04/21/2023] [Indexed: 05/19/2023] Open
Abstract
The body of evidence investigating human epidermal growth factor receptor-2 (HER2) directed therapy in patients with breast cancer (BC) has been growing within the last decade. Recently, the use of tyrosine kinase inhibitors (TKIs) has been of particular interest in the treatment of human malignancies. This literature commentary is intended to highlight the most recent findings associated with the widely-studied TKI agents and their clinical significance in improving the outcomes of HER2 positive BC.
Collapse